A Randomized, Double-blind, Parallel, Placebo-controlled, Multicenter, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety, and Immunogenicity of Botulinum Toxin Type A for Injection (HengLi®) in the Treatment of Trigeminal Neuralgia
Overview
- Phase
- Phase 2
- Intervention
- Botulinum Toxin Type A for Injection,also known as "HengLi®"
- Conditions
- Trigeminal Neuralgia
- Sponsor
- LKGS_277
- Enrollment
- 240
- Locations
- 1
- Primary Endpoint
- To evaluate the efficacy of different dosing regimens of Botulinum Toxin Type A for Injection (HengLi®) in the treatment of trigeminal neuralgia (TN), so as to determine the optimal dosing regimen of the best administration scheme of BoNTA
- Status
- Enrolling by Invitation
- Last Updated
- last year
Overview
Brief Summary
To evaluate the efficacy of different dosing regimens of Botulinum Toxin Type A for Injection (HengLi®) in the treatment of trigeminal neuralgia (TN), so as to determine the optimal dosing regimen of the best administration scheme of Botulinum Toxin Type A for Injection (HengLi®) in the treatment of TN.
Detailed Description
This study plans to enroll 240 subjects, and the efficacy measures \[VAS score, DSIS score, daily pain duration (if applicable), and number of daily pain episodes\] will be collected from subjects using the electronic Patient-Reported Outcomes (ePRO) throughout the study. The study period mainly consists of a screening period (14 days before the first dose), a double-blind treatment period (from the first dose to Week 12), and an extension period (from Week 13 to Week 52), including a maximum of 4 treatment cycles (each cycle lasts 12 week)
Investigators
LKGS_277
Linna Wang , director
Lanzhou Institute of Biological Products Co., Ltd
Eligibility Criteria
Inclusion Criteria
- •Understand and voluntarily sign the written ICF;
- •Male or female 18 to 75 years of age (inclusive), able to provide legal identification;
- •Subjects clinically diagnosed as classical or idiopathic TN, with pain in one or two divisions (diagnostic criteria in the International Classification of Headache Disorders, 3rd Edition \[ICHD-3\], see Appendix 6);
- •Have a mean daily VAS score of ≥ 40 mm for 7 consecutive days during the screening period, with mean number of daily episodes ≥ 2, and duration of pain ≥ 3 months at screening;
- •Have a clear consciousness, the ability to perceive and resolve pain, the ability to understand and cooperate with the clinical study process, and the ability to comply with the requirements of the study protocol until completion of the study;
- •Prior first-line drug therapy (carbamazepine, oxcarbazepine) for TN;
- •Women of childbearing potential (WOCBP) should have a negative pregnancy test within 7 days prior to the first dose, and subjects and their partners should have no pregnancy plan and promise to use a medically acceptable contraceptive measure (e.g., intrauterine device \[IUD\], contraceptive pill or condom) during the study drug treatment period and within 3 months after the last dose of study drug; Note: WOCBP is defined as non-postmenopausal women who have experienced menarche and have not undergone sterilization (hysterectomy or bilateral adnexectomy) or other causes of permanent infertility (e.g., mullerian agenesis) identified by investigator. Postmenopause is defined as amenorrhea for ≥12 months without other biological or physiological causes.
Exclusion Criteria
- •Subjects with TN who have a history of surgical treatment, such as percutaneous radiofrequency thermocoagulation of trigeminal ganglion, Meckel's cave compression, stereotactic gamma knife radiotherapy. and microvascular decompression;
- •Change in the dose and type of drugs for treatment of TN changed within 4 weeks prior to the first dose (including carbamazepine, oxcarbazepine, gabapentin, lamotrigine, etc.);
- •Subjects who have received injection therapy (magnesium sulfate injection), physical therapy, or traditional Chinese medicine treatment of TN within 4 weeks prior to the first dose, such as ultrashort wave, magnetic therapy, acupuncture, traditional Chinese medicines, etc.;
- •Patients who have received any botulinum agent within 6 months prior to the first dose;
- •Patients with secondary TN confirmed by magnetic resonance imaging (MRI);
- •Patients with systemic neuromuscular junction disorders, such as myasthenia, Eaton Lambert syndrome, amyotrophic (spinal cord) lateral sclerosis, multiple sclerosis, etc.;
- •Subjects who have used drugs affecting neuromuscular junction within 7 days prior to the first dose (for example, aminoglycoside antibiotics \[e.g., gentamycin, etc.\], quinine, and penicillamine) or need to use the above drugs, cholinesterase antagonists, succinylcholine, curare-like depolarizing antagonists, magnesium sulfate, quinidine, calcium channel blockers (excluding antihypertensive agents such as amlodipine besylate and nifedipine), lincomycin, polymyxin, etc. during the conduct of the clinical trial;
- •There are conditions that investigator believes may affect pain assessment, such as skin disorders in the affected skin areas and may affect sensation, or the recommended injection sites have localized infection or are locally accompanied by other skin disorders;
- •Concurrent or prior hemorrhagic conditions, or intake of anticoagulants \[e.g. heparin, coumarins, non-vitamin K antagonists, oral anticoagulants (e.g., apixaban, dabigatran, edoxaban, rivaroxaban), but aspirin and other platelet aggregation inhibitors such as ticlopidine, clopidogrel, prasugrel, abciximab, eptifibatide, and tirofiban are allowed\] within 10 days prior to injection;
- •Chronic systemic diseases, which may affect subject's participation in the study as assessed by investigator, including but not limited to:
Arms & Interventions
Botulinum Toxin Type A for Injection(5U/site）
5U/site
Intervention: Botulinum Toxin Type A for Injection,also known as "HengLi®"
Botulinum Toxin Type A for Injection（2.5U/site）
2.5U/site
Intervention: Botulinum Toxin Type A for Injection,also known as "HengLi®"
placebo
0U/site
Intervention: Botulinum Toxin Type A for Injection,also known as "HengLi®"
Outcomes
Primary Outcomes
To evaluate the efficacy of different dosing regimens of Botulinum Toxin Type A for Injection (HengLi®) in the treatment of trigeminal neuralgia (TN), so as to determine the optimal dosing regimen of the best administration scheme of BoNTA
Time Frame: Week 12
Change in mean visual analogue scale (VAS) score at Week 12 from the mean VAS score over one week at baseline. for VAS,Pain was scored on a scale of 0 to10, with 0 indicating no pain, 10 indicating severe pain, and the middle part indicating varying degrees of pain.
Secondary Outcomes
- To evaluate the duration of response to different dosing regimens of Botulinum Toxin Type A for Injection (HengLi®) in the treatment of TN.(week4,week8,week 12)
- To evaluate the efficacy of Botulinum Toxin Type A for Injection (HengLi®) following multiple doses.(from date of randomization until the date of no response(improvement in VAS score from baseline < 50% )or date of study completion,whichever came first,assessed up to 52 weeks)